DUBLIN, Dec. 5, 2014 /PRNewswire/ --
(http://www.researchandmarkets.com/research/6ptjf8/global_oncology) has announced the addition of the "Global Oncology Biosimilars Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.
The analysts forecast the Global Oncology Biosimilars market to grow at a CAGR of 29.87 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Oncology Biosimilars market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales biosimilars used in cancer treatment.
The report, Global Oncology Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Oncology Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
One key trend in this market is the outsourcing of biosimilar manufacturing activities to developing countries. Outsourcing the manufacture of biosimilar products decreases the overall cost of manufacturing biosimilars, thereby making them affordable to patients.
According to the report, one of the main drivers of the market is the increase in the number of patent expiries. A number of biopharmaceutical patents are either about to expire in the near future or have already expired. This has helped propel the growth of vendors in the market.
Further, the report states that one of the major challenges that the market faces is the risk related to the failure of the drug in the market. The high investment required during the developmental stage of drugs creates risks for vendors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Segmentation by Application
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
17. Key Vendor Analysis
18. Other Reports in this Series
Companies Mentioned:
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Hospira
- Mylan
- Sandoz
- 3SBio
- Abbvie
- AstraZeneca
- BioXpress Therapeutics
- Boehringer Ingelheim
- Coherus Biosciences
- Intas Pharmaceuticals
- Merck Serono
- Pfizer
- Wockhardt
For more information visit http://www.researchandmarkets.com/research/6ptjf8/global_oncology
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
